Search Results - "Olivier Hermine"

ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment? by Petrov, Dmitry, Mansfield, Colin, Moussy, Alain, Hermine, Olivier

“…Amyotrophic lateral sclerosis (ALS) is a devastating condition with an estimated mortality of 30,000 patients a year worldwide. The median reported survival…”
Get full text

Mitochondrial regulation of erythropoiesis in homeostasis and disease by Menon, Vijay, Slavinsky, Mary, Hermine, Olivier, Ghaffari, Saghi

“…Summary Erythroid cells undergo a highly complex maturation process, resulting in dynamic changes that generate red blood cells (RBCs) highly rich in…”
Get full text

Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis by Gotlib, Jason, Kluin-Nelemans, Hanneke C, George, Tracy I, Akin, Cem, Sotlar, Karl, Hermine, Olivier, Awan, Farrukh T, Hexner, Elizabeth, Mauro, Michael J, Sternberg, David W, Villeneuve, Matthieu, Huntsman Labed, Alice, Stanek, Eric J, Hartmann, Karin, Horny, Hans-Peter, Valent, Peter, Reiter, Andreas

“…Midostaurin is a multikinase inhibitor that includes mutant and nonmutant KIT D816V as a target. Its use in patients with advanced systemic mastocytosis,…”
Get full text

Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future by Valent, Peter, Akin, Cem, Hartmann, Karin, Nilsson, Gunnar, Reiter, Andreas, Hermine, Olivier, Sotlar, Karl, Sperr, Wolfgang R, Escribano, Luis, George, Tracy I, Kluin-Nelemans, Hanneke C, Ustun, Celalettin, Triggiani, Massimo, Brockow, Knut, Gotlib, Jason, Orfao, Alberto, Schwartz, Lawrence B, Broesby-Olsen, Sigurd, Bindslev-Jensen, Carsten, Kovanen, Petri T, Galli, Stephen J, Austen, K Frank, Arber, Daniel A, Horny, Hans-Peter, Arock, Michel, Metcalfe, Dean D

“…Mastocytosis is a term used to denote a heterogeneous group of conditions defined by the expansion and accumulation of clonal (neoplastic) tissue mast cells in…”
Get full text

Innate immune cells, major protagonists of sickle cell disease pathophysiology by Allali, Slimane, Maciel, Thiago Trovati, Hermine, Olivier, de Montalembert, Mariane

“…Sickle cell disease (SCD), considered the most common monogenic disease worldwide, is a severe hemoglobin disorder. Although the genetic and molecular bases…”
Get full text

Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study by Beaugerie, Laurent, Prof, Brousse, Nicole, Prof, Bouvier, Anne Marie, MD, Colombel, Jean Frédéric, Prof, Lémann, Marc, Prof, Cosnes, Jacques, Prof, Hébuterne, Xavier, Prof, Cortot, Antoine, Prof, Bouhnik, Yoram, Prof, Gendre, Jean Pierre, Prof, Simon, Tabassome, Prof, Maynadié, Marc, Prof, Hermine, Olivier, Prof, Faivre, Jean, Prof, Carrat, Fabrice, Prof

“…Summary Background Reports of an increased risk of lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease are…”
Get full text

Rituximab‐Bendamustine (R‐Benda) in MALT lymphoma complicating primary Sjögren syndrome (pSS) by Demaria, Lucie, Henry, Julien, Seror, Raphaele, Frenzel, Laurent, Hermine, Olivier, Mariette, Xavier, Nocturne, Gaetane

Get full text

Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma by Le Gouill, Steven, Thieblemont, Catherine, Oberic, Lucie, Moreau, Anne, Bouabdallah, Krimo, Dartigeas, Caroline, Damaj, Gandhi, Gastinne, Thomas, Ribrag, Vincent, Feugier, Pierre, Casasnovas, Olivier, Zerazhi, Hacène, Haioun, Corinne, Maisonneuve, Hervé, Houot, Roch, Jardin, Fabrice, Van Den Neste, Eric, Tournilhac, Olivier, Le Dû, Katell, Morschhauser, Franck, Cartron, Guillaume, Fornecker, Luc-Matthieu, Canioni, Danielle, Callanan, Mary, Béné, Marie C, Salles, Gilles, Tilly, Hervé, Lamy, Thierry, Gressin, Remy, Hermine, Olivier

“…The use of rituximab every 2 months for 3 years after immunochemotherapy and autologous stem-cell transplantation prolonged progression-free and overall…”
Get full text

Comment on Kieslinger et al. A Recurrent STAT5BN642H Driver Mutation in Feline Alimentary T Cell Lymphoma. Cancers 2021, 13, 5238 by Freiche, Valérie, Couronné, Lucile, Bruneau, Julie, Hermine, Olivier

“…We have read with great interest the recently published article by M. Kieslinger et al. in Cancers Journal [...]…”
Get full text

Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma by Wang, Michael L., Jurczak, Wojciech, Jerkeman, Mats, Trotman, Judith, Zinzani, Pier L., Belada, David, Boccomini, Carola, Flinn, Ian W., Giri, Pratyush, Goy, Andre, Hamlin, Paul A., Hermine, Olivier, Hernández-Rivas, José-Ángel, Hong, Xiaonan, Kim, Seok Jin, Lewis, David, Mishima, Yuko, Özcan, Muhit, Perini, Guilherme F., Pocock, Christopher, Song, Yuqin, Spurgeon, Stephen E., Storring, John M., Walewski, Jan, Zhu, Jun, Qin, Rui, Henninger, Todd, Deshpande, Sanjay, Howes, Angela, Le Gouill, Steven, Dreyling, Martin

“…A trial involving 523 patients with mantle-cell lymphoma randomly assigned patients to receive bendamustine plus rituximab or these drugs plus ibrutinib. At a…”
Get full text

Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network by Hermine, Olivier, Prof, Hoster, Eva, PhD, Walewski, Jan, MD, Bosly, André, MD, Stilgenbauer, Stephan, MD, Thieblemont, Catherine, MD, Szymczyk, Michal, MD, Bouabdallah, Reda, MD, Kneba, Michael, Prof, Hallek, Michael, Prof, Salles, Gilles, Prof, Feugier, Pierre, MD, Ribrag, Vincent, MD, Birkmann, Josef, MD, Forstpointner, Roswitha, MD, Haioun, Corinne, MD, Hänel, Mathias, MD, Casasnovas, René Olivier, MD, Finke, Jürgen, MD, Peter, Norma, MD, Bouabdallah, Kamal, MD, Sebban, Catherine, MD, Fischer, Thomas, Prof, Dührsen, Ulrich, Prof, Metzner, Bernd, MD, Maschmeyer, Georg, MD, Kanz, Lothar, Prof, Schmidt, Christian, MD, Delarue, Richard, MD, Brousse, Nicole, MD, Klapper, Wolfram, MD, Macintyre, Elizabeth, Prof, Delfau-Larue, Marie-Hélène, Prof, Pott, Christiane, MD, Hiddemann, Wolfgang, Prof, Unterhalt, Michael, PhD, Dreyling, Martin, Prof

“…Summary Background Mantle cell lymphoma is characterised by a poor long-term prognosis. The European Mantle Cell Lymphoma Network aimed to investigate whether…”
Get full text

Incidence, presentation, and prognosis of malignancies in ataxia-telangiectasia: a report from the French national registry of primary immune deficiencies by Suarez, Felipe, Mahlaoui, Nizar, Canioni, Danielle, Andriamanga, Chantal, Dubois d'Enghien, Catherine, Brousse, Nicole, Jais, Jean-Philippe, Fischer, Alain, Hermine, Olivier, Stoppa-Lyonnet, Dominique

“…Biallelic mutations in ATM cause ataxia-telangiectasia (AT), a rare inherited disease with a high incidence of cancer. Precise estimates of the risk,…”
Get full text

Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial by Gotlib, Jason, Reiter, Andreas, Radia, Deepti H., Deininger, Michael W., George, Tracy I., Panse, Jens, Vannucchi, Alessandro M., Platzbecker, Uwe, Alvarez-Twose, Iván, Mital, Andrzej, Hermine, Olivier, Dybedal, Ingunn, Hexner, Elizabeth O., Hicks, Lisa K., Span, Lambert, Mesa, Ruben, Bose, Prithviraj, Pettit, Kristen M., Heaney, Mark L., Oh, Stephen T., Sen, Jayita, Lin, Hui-Min, Mar, Brenton G., DeAngelo, Daniel J.

“…Advanced systemic mastocytosis (AdvSM) is a rare, KIT D816V-driven hematologic neoplasm characterized by mast cell infiltration and shortened survival. We…”
Get full text

Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network by Hoster, Eva, Rosenwald, Andreas, Berger, Françoise, Bernd, Heinz-Wolfram, Hartmann, Sylvia, Loddenkemper, Christoph, Barth, Thomas F E, Brousse, Nicole, Pileri, Stefano, Rymkiewicz, Grzegorz, Kodet, Roman, Stilgenbauer, Stephan, Forstpointner, Roswitha, Thieblemont, Catherine, Hallek, Michael, Coiffier, Bertrand, Vehling-Kaiser, Ursula, Bouabdallah, Réda, Kanz, Lothar, Pfreundschuh, Michael, Schmidt, Christian, Ribrag, Vincent, Hiddemann, Wolfgang, Unterhalt, Michael, Kluin-Nelemans, Johanna C, Hermine, Olivier, Dreyling, Martin H, Klapper, Wolfram

“…Mantle-cell lymphoma (MCL) is a rather aggressive B-cell malignancy whose considerable variability of individual outcome is associated with clinical…”
Get full text

Lessons to Learn From Low-Dose Cyclosporin-A: A New Approach for Unexpected Clinical Applications by Flores, Camila, Fouquet, Guillemette, Moura, Ivan Cruz, Maciel, Thiago Trovati, Hermine, Olivier

“…Cyclosporin-A has been known and used for a long time, since its "fast track" approval in the early 80's. This molecule has rapidly demonstrated unexpected…”
Get full text

CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte by Delarue, Richard, Haioun, Corinne, Ribrag, Vincent, Brice, Pauline, Delmer, Alain, Tilly, Herve, Salles, Gilles, Van Hoof, Achiel, Casasnovas, Olivier, Brousse, Nicole, Lefrere, Francois, Hermine, Olivier

“…Treatment of mantle cell lymphoma (MCL) in younger patients remains a challenge. We report results of a phase 2 trial using cytarabine and rituximab as…”
Get full text

Convalescent plasma improves overall survival in patients with B-cell lymphoid malignancy and COVID-19: a longitudinal cohort and propensity score analysis by Hueso, Thomas, Godron, Anne-Sophie, Lanoy, Emilie, Pacanowski, Jérôme, Levi, Laura I., Gras, Emmanuelle, Surgers, Laure, Guemriche, Amina, Meynard, Jean-Luc, Pirenne, France, Idri, Salim, Tiberghien, Pierre, Morel, Pascal, Besson, Caroline, Duléry, Rémy, Lamure, Sylvain, Hermine, Olivier, Gagneux-Brunon, Amandine, Freymond, Nathalie, Grabar, Sophie, Lacombe, Karine

“…Patients with hematological malignancy and COVID-19 display a high mortality rate. In such patients, immunosuppression due to underlying disease and previous…”
Get full text

Immune interventions in COVID-19: a matter of time? by Plaçais, Léo, Richier, Quentin, Noël, Nicolas, Lacombe, Karine, Mariette, Xavier, Hermine, Olivier

“…As the COVID-19 pandemic is still ongoing, and considering the lack of efficacy of antiviral strategies to this date, and the reactive hyperinflammation…”
Get full text

Cis-perturbation of cancer drivers by the HTLV-1/BLV proviruses is an early determinant of leukemogenesis by Rosewick, Nicolas, Durkin, Keith, Artesi, Maria, Marçais, Ambroise, Hahaut, Vincent, Griebel, Philip, Arsic, Natasa, Avettand-Fenoel, Véronique, Burny, Arsène, Charlier, Carole, Hermine, Olivier, Georges, Michel, Van den Broeke, Anne

“…Human T-cell leukaemia virus type-1 (HTLV-1) and bovine leukaemia virus (BLV) infect T- and B-lymphocytes, respectively, provoking a polyclonal expansion that…”
Get full text

Meta-Analysis on the Use of Zidovudine and Interferon-Alfa in Adult T-Cell Leukemia/Lymphoma Showing Improved Survival in the Leukemic Subtypes by BAZARBACHI, Ali, PLUMELLE, Yves, RAMOS, Juan Carlos, TORTEVOYE, Patricia, OTROCK, Zaher, TAYLOR, Graham, GESSAIN, Antoine, HARRINGTON, William, PANELATTI, Gérard, HERMINE, Olivier

“…Human T-cell lymphotropic virus type-I-associated adult T-cell leukemia/lymphoma (ATL) is an aggressive, chemotherapy-resistant malignancy. Multiple small…”
Get full text